These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8132366)

  • 21. The influence of third-generation cephalosporins on the aerobic intestinal flora.
    Guggenbichler JP; Kofler J; Allerberger F
    Infection; 1985; 13 Suppl 1():S137-9. PubMed ID: 4055044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The influence of cefdinir on the intestinal bacterial flora].
    Iwata S; Kawahara K; Ikeda M; Isohata E; Kin Y; Kusumoto Y; Sato Y; Akita H; Nanri S; Oikawa T
    Jpn J Antibiot; 1992 Jan; 45(1):28-47. PubMed ID: 1495195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Faecal excretion of ciprofloxacin after a single oral dose and its effect on faecal bacteria in healthy volunteers.
    Pecquet S; Ravoire S; Andremont A
    J Antimicrob Chemother; 1990 Jul; 26(1):125-9. PubMed ID: 2211433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers.
    Bächer K; Schaeffer M; Lode H; Nord CE; Borner K; Koeppe P
    J Antimicrob Chemother; 1992 Sep; 30(3):365-75. PubMed ID: 1452502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Shedding of Clostridium difficile, fecal beta-lactamase activity, and gastrointestinal symptoms in 51 volunteers treated with oral cefixime.
    Chachaty E; Bourneix C; Renard S; Bonnay M; Andremont A
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1432-5. PubMed ID: 8363371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Influence of S-1108 on intestinal bacterial flora].
    Iwata S; Kawahara K; Isohata E; Kin Y; Yokota T; Kusumoto Y; Sato Y; Akita H; Oikawa T; Sunakawa K
    Jpn J Antibiot; 1993 Dec; 46(12):1045-62. PubMed ID: 8107268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [In vitro activity of several cytostatic drugs against aerobic and anaerobic intestinal bacteria].
    Vetere A; Giuliano M; Pantosti A; Panichi G
    Boll Ist Sieroter Milan; 1984; 63(6):505-9. PubMed ID: 6534396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of quinupristin/dalfopristin (RP59500) on the faecal microflora in healthy volunteers.
    Scanvic-Hameg A; Chachaty E; Rey J; Pousson C; Ozoux ML; Brunel E; Andremont A
    J Antimicrob Chemother; 2002 Jan; 49(1):135-9. PubMed ID: 11751777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ecological effect of gatifloxacin on the normal human intestinal microflora.
    Edlund C; Nord CE
    J Chemother; 1999 Feb; 11(1):50-3. PubMed ID: 10078781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The in vitro activity and beta-lactamase stability of cefpirome (HR 810), a pyridine cephalosporin agent active against staphylococci, Enterobacteriaceae and Pseudomonas aeruginosa.
    Neu HC; Chin NX; Labthavikul P
    Infection; 1985; 13(3):146-55. PubMed ID: 3928497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers.
    Pletz MW; Rau M; Bulitta J; De Roux A; Burkhardt O; Kruse G; Kurowski M; Nord CE; Lode H
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3765-72. PubMed ID: 15388432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of loracarbef on the normal oropharyngeal and intestinal microflora.
    Nord CE; Grahnen A; Eckernäs SA
    Scand J Infect Dis; 1991; 23(2):255-60. PubMed ID: 1853174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features.
    Jones RN
    Pediatr Infect Dis J; 1995 Jul; 14(7 Suppl):S77-83. PubMed ID: 7567314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of gemifloxacin on the normal human intestinal microflora.
    Barker PJ; Sheehan R; Teillol-Foo M; Palmgren AC; Nord CE
    J Chemother; 2001 Feb; 13(1):47-51. PubMed ID: 11233800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Betalactam therapy and intestinal flora.
    Novelli A; Mazzei T; Fallani S; Dei R; Cassetta MI; Conti S
    J Chemother; 1995 May; 7 Suppl 1():25-31. PubMed ID: 8618110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of beta-lactamase-producing anaerobes to prevent ceftriaxone from degrading intestinal resistance to colonization.
    Léonard F; Andremont A; Leclerq B; Labia R; Tancrède C
    J Infect Dis; 1989 Aug; 160(2):274-80. PubMed ID: 2788196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of norfloxacin on the faecal flora in patients with complicated urinary tract infections.
    Boerema JB; Olthof BJ; van Saene HK
    Scand J Infect Dis Suppl; 1986; 48():27-31. PubMed ID: 3095916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ceftibuten pharmacokinetics and pharmacodynamics. Focus on paediatric use.
    Kearns GL; Young RA
    Clin Pharmacokinet; 1994 Mar; 26(3):169-89. PubMed ID: 8194281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect on the human normal microflora of oral antibiotics for treatment of urinary tract infections.
    Edlund C; Nord CE
    J Antimicrob Chemother; 2000 Aug; 46 Suppl A():41-48. PubMed ID: 10969051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative susceptibility of clinical isolates producing extended spectrum beta-lactamases to ceftibuten: effect of large inocula.
    Medeiros AA; Crellin J
    Pediatr Infect Dis J; 1997 Mar; 16(3 Suppl):S49-55. PubMed ID: 9076836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.